Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation.
Marco GalluzzoMarina TalamontiClara De SimoneSimone D'AdamioGaia MorettaSara TamboneGiacomo CaldarolaMaria Concetta FargnoliKetty PerisLuca BianchiPublished in: Expert opinion on biological therapy (2018)
Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results.